VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference

Rhea-AI Summary

VYNE Therapeutics Inc. (Nasdaq: VYNE) announced participation in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference on March 30, 2023. CEO David Domzalski and Chief Scientific Officer Dr. Iain Stuart will engage in a fireside chat at 3:30 PM ET. Investors can also schedule 1-on-1 meetings during the event. The discussion will cover the company’s innovative therapies for immuno-inflammatory conditions, including their lead programs, VYN201 and VYN202. A replay of the webcast will be available on the company's website for 90 days post-conference. For details, visit vynetherapeutics.com.

BRIDGEWATER, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference being held on Thursday, March 30, 2023. Management will also be available for 1-on-1 meetings with investors.

HCW Conference Presentation Details

Fireside Chat:	Thursday, March 30, 2023, at 3:30 PM ET
Speakers:	David Domzalski, President and Chief Executive Officer Dr. Iain Stuart, Chief Scientific Officer
Registration:	Webcast Link

The replay of the webcast will be available on the VYNE website for 90 days following the conference.

About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary bromodomain & extra-terminal (BET) domain platform includes lead programs, VYN201 (locally administered pan-BETi), and VYN202 (orally available selective-BETi), and access to a library of small molecule BET inhibitors for the potential treatment of immuno-inflammatory conditions licensed from Tay Therapeutics Limited.

For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com

FAQ

What is VYNE Therapeutics presenting at the March 30, 2023 conference?

VYNE Therapeutics will present its innovative therapies for immuno-inflammatory conditions during a fireside chat at the H.C. Wainwright conference.

Who are the speakers at the VYNE Therapeutics conference event?

David Domzalski, President and CEO, and Dr. Iain Stuart, Chief Scientific Officer, will be the speakers.

What time does VYNE Therapeutics' fireside chat start?

The fireside chat will start at 3:30 PM ET on March 30, 2023.

Where can I watch the VYNE Therapeutics conference webcast?

The webcast can be watched through the registration link provided by VYNE Therapeutics.

How long will the VYNE Therapeutics webcast replay be available?

The replay of the webcast will be available for 90 days following the conference.